157 E 32nd St. New York, NY 10016 212-689-6791
Array
(
    [0] => 2773
    [1] => 2772
    [2] => 2771
    [3] => 2770
)

I am text block. Click edit button to change this text.Molecular Testing Panel Increases Likelihood of Performing Correct Surgery for Thyroid Cancer Patients
News Medical
July31, 2014
http://www.news-medical.net/news/20140726/Molecular-testing-panel-increases-likelihood-of-performing-correct-surgery-for-thyroid-cancer-patients.aspx

EMA Approves Eisai’s Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer
MarketWatch
July 31, 2014
http://www.marketwatch.com/story/ema-approves-eisais-lenvatinib-for-accelerated-assessment-in-radioiodine-refractory-differentiated-thyroid-cancer-2014-07-30

CEL-SCI expands late-stage head and neck trial
Nasdaq
July, 2014
http://www.nasdaq.com/article/celsci-expands-latestage-head-and-neck-cancer-trial-into-sri-lanka-20140717-00479

Nexavar Approval Widens
ThyCa: Thyroid Cancer
July, 2014
http://www.thyca.org/news/newsnotes0614#nexavar